Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARASENS Phase III trial of darolutamide with docetaxel + ADT in metastatic hormone‑sensitive prostate cancer
jRCT2080223461Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide + docetaxel + ADT with Placebo + docetaxel + ADT (2 arms). Started Feb 2017; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080223461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223461.